447 related articles for article (PubMed ID: 17922398)
1. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life.
Nair N; Gans H; Lew-Yasukawa L; Long-Wagar AC; Arvin A; Griffin DE
J Infect Dis; 2007 Nov; 196(9):1339-45. PubMed ID: 17922398
[TBL] [Abstract][Full Text] [Related]
2. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
Gans HA; Yasukawa LL; Alderson A; Rinki M; DeHovitz R; Beeler J; Audet S; Maldonado Y; Arvin AM
J Infect Dis; 2004 Jul; 190(1):83-90. PubMed ID: 15195246
[TBL] [Abstract][Full Text] [Related]
3. Measles vaccine immunogenicity in 6- versus 15-month-old infants born to mothers in the measles vaccine era.
Johnson CE; Nalin DR; Chui LW; Whitwell J; Marusyk RG; Kumar ML
Pediatrics; 1994 Jun; 93(6 Pt 1):939-44. PubMed ID: 8190581
[TBL] [Abstract][Full Text] [Related]
4. Immune response to measles vaccine in 6 month old infants in Papua New Guinea.
Kurubi J; Vince J; Ripa P; Tefuarani N; Riddell M; Duke T
Trop Med Int Health; 2009 Feb; 14(2):167-73. PubMed ID: 19171008
[TBL] [Abstract][Full Text] [Related]
5. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
[TBL] [Abstract][Full Text] [Related]
6. Follow-up of infants given measles vaccine at 6 months of age: antibody and CMI responses to MMRII at 15 months of age and antibody levels at 27 months of age.
Carson MM; Spady DW; Beeler JA; Krezolek MP; Audet S; Pabst HF
Vaccine; 2005 May; 23(25):3247-55. PubMed ID: 15837229
[TBL] [Abstract][Full Text] [Related]
7. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I
J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129
[TBL] [Abstract][Full Text] [Related]
8. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
[TBL] [Abstract][Full Text] [Related]
9. Humoral and cellular immune response after measles vaccination in Taiwan.
Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
[TBL] [Abstract][Full Text] [Related]
10. Immune response to measles, mumps & rubella vaccine at 9, 12 & 15 months of age.
Singh R; John TJ; Cherian T; Raghupathy P
Indian J Med Res; 1994 Oct; 100():155-9. PubMed ID: 7851964
[TBL] [Abstract][Full Text] [Related]
11. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity.
Maldonado YA; Lawrence EC; DeHovitz R; Hartzell H; Albrecht P
Pediatrics; 1995 Sep; 96(3 Pt 1):447-50. PubMed ID: 7651776
[TBL] [Abstract][Full Text] [Related]
12. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months.
Gans H; Yasukawa L; Rinki M; DeHovitz R; Forghani B; Beeler J; Audet S; Maldonado Y; Arvin AM
J Infect Dis; 2001 Oct; 184(7):817-26. PubMed ID: 11528592
[TBL] [Abstract][Full Text] [Related]
13. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
14. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine.
Ovsyannikova IG; Pankratz VS; Vierkant RA; Jacobson RM; Poland GA
J Infect Dis; 2006 Mar; 193(5):655-63. PubMed ID: 16453260
[TBL] [Abstract][Full Text] [Related]
15. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants.
D'Angio CT; Boohene PA; Mowrer A; Audet S; Menegus MA; Schmid DS; Beeler JA
Pediatrics; 2007 Mar; 119(3):e574-9. PubMed ID: 17332177
[TBL] [Abstract][Full Text] [Related]
16. Seroconversion after measles vaccination at nine and fifteen months of age.
Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S
Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768
[TBL] [Abstract][Full Text] [Related]
17. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.
Fiebelkorn AP; Coleman LA; Belongia EA; Freeman SK; York D; Bi D; Kulkarni A; Audet S; Mercader S; McGrew M; Hickman CJ; Bellini WJ; Shivakoti R; Griffin DE; Beeler J
J Infect Dis; 2016 Apr; 213(7):1115-23. PubMed ID: 26597262
[TBL] [Abstract][Full Text] [Related]
18. Antibody response after measles immunization.
Ariyasriwatana C; Kalayanarooj S; Pattamadilok S
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S701-6. PubMed ID: 14700170
[TBL] [Abstract][Full Text] [Related]
19. Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response.
Halperin SA; McGrath P; Smith B; Houston T
J Pediatr; 2000 Jun; 136(6):789-94. PubMed ID: 10839878
[TBL] [Abstract][Full Text] [Related]
20. [The study of countermeasures on measles control in infants].
Wang L; Sun L; Jiang Z; Kang S; Liu Y; Jiang X
Zhonghua Liu Xing Bing Xue Za Zhi; 2001 Feb; 22(1):49-50. PubMed ID: 11860845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
